- Home
- CUE vs MDAI Comparison
CUE vs MDAI Comparison
Compare CUE & MDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- MDAI
- Stock Information
- Founded
- CUE 2014
- MDAI 2013
- Country
- CUE United States
- MDAI United States
- Employees
- CUE N/A
- MDAI N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- MDAI Medical/Dental Instruments
- Sector
- CUE Health Care
- MDAI Health Care
- Exchange
- CUE Nasdaq
- MDAI Nasdaq
- Market Cap
- CUE 48.0M
- MDAI 51.5M
- IPO Year
- CUE 2018
- MDAI N/A
- Fundamental
- Price
- CUE $0.74
- MDAI $2.92
- Analyst Decision
- CUE Strong Buy
- MDAI Strong Buy
- Analyst Count
- CUE 3
- MDAI 2
- Target Price
- CUE $3.00
- MDAI $4.75
- AVG Volume (30 Days)
- CUE 323.3K
- MDAI 674.6K
- Earning Date
- CUE 08-13-2025
- MDAI 08-11-2025
- Dividend Yield
- CUE N/A
- MDAI N/A
- EPS Growth
- CUE N/A
- MDAI N/A
- EPS
- CUE N/A
- MDAI N/A
- Revenue
- CUE $7,991,000.00
- MDAI $29,962,000.00
- Revenue This Year
- CUE N/A
- MDAI N/A
- Revenue Next Year
- CUE $23.84
- MDAI $15.14
- P/E Ratio
- CUE N/A
- MDAI N/A
- Revenue Growth
- CUE 13.83
- MDAI 55.21
- 52 Week Low
- CUE $0.45
- MDAI $0.82
- 52 Week High
- CUE $1.99
- MDAI $3.25
- Technical
- Relative Strength Index (RSI)
- CUE 51.10
- MDAI 75.68
- Support Level
- CUE $0.65
- MDAI $2.56
- Resistance Level
- CUE $0.83
- MDAI $3.21
- Average True Range (ATR)
- CUE 0.07
- MDAI 0.20
- MACD
- CUE 0.01
- MDAI 0.07
- Stochastic Oscillator
- CUE 30.43
- MDAI 89.74
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About MDAI Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.